This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide? - Teaching Note
Eades, Kenneth M.; Matos, PedroTeaching Note DARDEN-F-1660TN-EFinanceTeaching note for product F-1660Starting at €0.00
-
Genzyme and Relational Investors: Science and Business Collide?
Eades, Kenneth M.; Matos, Pedro; Green, RickCase DARDEN-F-1660-EFinanceThe chairman and CEO of the Genzyme Corporation, one of the country’s top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.Starting at €8.20
-
When Competition Isn't Enough: Rural Health in Southwest Virginia (B)
Matherne; G. Paul; Goldberg; Rebecca; Bermel; Peggy; Fox; Brennan; Minogue; Kevin; Oberleitner; Ryan; Punches; Charlie; Rose; CarolineCase DARDEN-S-0315-EStrategyIn this B case; the follow-up to S-0314; Marissa Levine; the Virginia Commissioner of Health; considers reports for and against the merger of two health care entities in rural Virginia; as she decides whether to issue a waiver to allow it. This case set explores the differences in and conflicts among the interests of for-profit health care systems; of rural; low-income residents; and of federal; state; and local governments. It allows students to...Starting at €5.74
-
When Competition Isn't Enough: Rural Health in Southwest Virginia (C)
Matherne; G. Paul; Goldberg; Rebecca; Bermel; Peggy; Fox; Brennan; Minogue; Kevin; Oberleitner; Ryan; Punches; Charlie; Rose; CarolineCase DARDEN-S-0316-EStrategyThis optional C case follows S-0314 and S-0315; and describes the results of decisions on whether to allow a merger of two health care entities in rural Virginia. This case set explores the differences in and conflicts among the interests of for-profit health care systems; of rural; low-income residents; and of federal; state; and local governments. It allows students to engage in an in-depth discussion of the sometimes emotional issue of rural h...Starting at €5.74
-
When Competition Isn't Enough: Rural Health in Southwest Virginia (A)
Matherne; G. Paul; Goldberg; Rebecca; Bermel; Peggy; Fox; Brennan; Minogue; Kevin; Oberleitner; Ryan; Punches; Charlie; Rose; CarolineCase DARDEN-S-0314-EStrategyMark Seidman at the Federal Trade Commission is evaluating a proposed merger between two health care entities and competing market leaders in southwest Virginia. The rural region is characterized by poverty; unemployment; and poor population health indicators relative to the rest of the state. The merger would form a virtual monopoly; normally prohibited by federal consumer protection laws; but the two companies assert that it would allow them to...Starting at €8.20